4.6025
0.1725 (3.89%)
0.1725 (3.89%)
Upgrade to Real-Time
Regular Market
Volume | 349,101 |
|
|||||
News | - | ||||||
Day High | 4.68 | Low High |
|||||
Day Low | 4.36 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Biora Therapeutics Inc | BIOR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.40 | 4.36 | 4.68 | 4.43 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,592 | 349,101 | $ 4.55 | $ 1,589,016 | - | 1.95 - 28.75 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:54:42 | 1 | $ 4.61 | USD |
Biora Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 41.87M | 9.10M | 6.58M | $ 25.61M | $ - | -67.25 | -0.30 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 24.83M | 9.10% |
Biora Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIOR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.26 | 4.80 | 3.9231 | 4.31 | 946,354 | 0.3425 | 8.04% |
1 Month | 3.665 | 7.68 | 1.95 | 5.68 | 7,690,447 | 0.9375 | 25.58% |
3 Months | 8.25 | 8.525 | 1.95 | 5.61 | 3,555,019 | -3.65 | -44.21% |
6 Months | 16.7775 | 28.75 | 1.95 | 10.35 | 2,510,987 | -12.18 | -72.57% |
1 Year | 21.50 | 28.75 | 1.95 | 12.19 | 2,323,834 | -16.90 | -78.59% |
3 Years | 21.50 | 28.75 | 1.95 | 12.19 | 2,323,834 | -16.90 | -78.59% |
5 Years | 21.50 | 28.75 | 1.95 | 12.19 | 2,323,834 | -16.90 | -78.59% |
Biora Therapeutics Description
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States. |